How CRISPR Could Add to the Soaring Cost of Medicine

Jim Kozubeck, STAT, 26 June 2017,

With many companies pursuing medical uses of gene editing, it is only a matter of time until treatments become commercially available.  Despite promises, the cost of these treatments may prevent their widespread adoption.  In this opinion piece Jim Kozubek discusses the price tag of current gene therapy treatments and the possible future of these technologies.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply